Persistent Systems Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/dee98soqhkqqxmtp36m92nv9.pdf

Key Takeaways


Demand Environment

Kalra: "All I can say is, the environment has been cautious. Decision making has been slow. If the environment becomes a little bit better and not just for us, for everyone, I think things will be easier."

Vertical Performance

VerticalTrendCommentary
BFSI▲ Strong growthLed all verticals at 30.7% YoY; Persistent is brought in as a challenger to larger incumbents for AI discussions and optimizations; expected to lead growth this year.
Software & Hi-Tech▲ Solid growthGrew 14.1% YoY; ranked second in expected growth contribution for the year.
Healthcare & Life Sciences▼ QoQ declineDeclined 2.1% QoQ due to planned on-site to offshore transition at the largest client; cost overlap from subcontractors staying flat while offshore headcount ramped pressured margins. Growth outside the top customer was sharp.
Europe▲ Strong geographyLed all regions with 37.5% YoY growth.
North America▲ Solid growthGrew 17.4% YoY.
India▲ Solid growthGrew 18.3% YoY.
Rest of World▼ DeclineDeclined 1.7% YoY.
Kalra: "Will it continue the growth at the 30%, 40%, 60% year-on-year that we had last year, may not be, but there'll be definitely growth in healthcare as well."

AI & Platform Strategy

Kalra: "Whether people buy SASVA or not, whether people SASVA-based services or not, it kind of lands us in a very good, competitive, differentiated position in our business."

Margins & Cost Structure

Margin walk (QoQ)Impact
Lower ESOP cost+230 bps
Absence of earn-out reversal–60 bps
Onsite retention & delayed ramp-ups–100 bps
Higher amortization–40 bps
Unfavorable currency–40 bps
Net change → 15.5%–10 bps
Kalra: "So, there is a little bit of uncertainty continuum that is happening and the order book is dependent on people taking decisions. So, as I said before, pipeline is good, we'll let it pan out. And as a cautionary measure to make sure that we are being prudent, we have delayed the increase by a quarter."

Deal Wins & Order Book


People & Organization


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue aspirationReach $2 billion in revenue through profitable, sustainable growth, "not at any cost"By end of FY27 (March 2027)
Margin improvementImprove trading margin by 200-300 bpsBy FY27
ESOP cost trajectoryRemain flat for next couple of quarters, then decline furtherFY27 over FY26
Healthcare verticalNo further degrowth expected; will be a growth vertical this yearFY26
Wage hikeDelayed by one quarter; compensation decision at year-end if conditions improveQ2 FY26 rollout / year-end compensation call
Effective tax rate22.5% to 23.5% full-year rangeFY26
Vertical focusDeepen existing verticals (software/hi-tech, BFSI, healthcare/life sciences) before evaluating new onesNext 1-3 years
Acquisition strategyCapability-led, smaller tuck-in acquisitions; scaled acquisition only for a good European assetOngoing

Key Metrics

MetricQ1 FY26
Revenue (USD)$389.7 million, +3.9% QoQ and +18.8% YoY
Revenue (INR)₹3,333.59 crore, +2.8% QoQ and +21.8% YoY
Constant currency revenue growth3.3% QoQ
EBIT margin15.5%, +150 bps YoY; net decrease of 10 bps QoQ after tailwinds and headwinds
EBIT (INR)₹517.81 crore, +2.5% QoQ and +34.8% YoY
Profit after tax (PAT)₹424.94 crore, +7.4% QoQ and +38.7% YoY; PAT margin 12.7%
Earnings per share₹27.4, +36.5% YoY
Total Contract Value (TCV)$520.8 million; new bookings TCV $337.0 million
Annual Contract Value (ACV)$385.3 million; ACV from new bookings $211.8 million
Book-to-bill ratio1.3–1.4 in the last two quarters, down from 1.5–1.6 historically (per an analyst's math)
North America revenue growth17.4% YoY in USD
Europe revenue growth37.5% YoY in USD
BFSI vertical revenue growth30.7% YoY
Software, Hi-tech & Emerging Industries revenue growth14.1% YoY
Healthcare & Life Sciences revenue growth12.4% YoY; -2.1% QoQ
Total headcount25,314, +1,821 YoY and +746 QoQ
Trailing 12-month attrition13.9%, up from 11.9% in Q1 last year
Return on Capital Employed (RoCE, excluding cash)43.8%, +510 bps YoY
Billed DSO56 days, improved 2 days QoQ
Operating cash flow to PAT98.6%
Effective tax rate23.5%; expected full-year range 22.5%–23.5%
Forward contracts outstanding$440 million at average rate ₹86.90 per dollar
SASVA-related patents55-plus, up from 35 in Q4 FY25
Annual wage hikePostponed by a quarter from the usual July cycle